Abstract
Calcium ions play an essential role in the contractility of skeletal and smooth muscle and of both the normal and diseased heart. Calcium channel blockers (CCBs), also termed calcium antagonists, calcium entry blockers or more simply calcium blockers (in French, anticalciques), inhibit the inward movement of calcium in depolarised muscles. This calcium influx occurs through L-type (long-lasting, large-current, or slow), voltage-dependent calcium channels. This results in relaxation of vascular smooth muscle and reduction of cardiac contractility. Although belonging to different chemical families (Fig. 1.1), CCBs are often assumed to be a pharmacologically homogeneous family of drugs. The common property of CCBs is their capacity to relax calcium-evoked contraction of depolarised smooth muscle (Godfraind and Polster 1968; Godfraind and Kaba 1969). Refined pharmacological studies show that variations in chemical structure may result in differences in binding sites, tissue selectivity, and, consequently, clinical activity and therapeutic indications (Godfraind et al. 1986).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Böhm M, Schwinger RHG, Erdmann E (1990) Different cardiodepressant potency of various calcium antagonists in human myocardium. Am J Cardiol 65: 1039–1041
Boyd RA, Giacomini JC, Giacomini KM (1988) Species differences in the negative isotropic response of 1,4-dihydropyridine calcium channel blockers in myocardium. J Cardiovasc Pharmacol 12: 650–657
Cohn JN, Ziesche S, Smith R et al (1997) Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 96 (3): 856–863
Cristofori P, Terron A, Michelli D, Bertolini G, Gaviraghi G (1994) Lacidipine: experi- mental evidence of vasculoprotective properties. J Cardiovas Pharmacol 23: S90 - S93
Feron O, Octave JN, Christen MO, Godfraind T (1994) Quantification of two splicing events in the L-type calcium channel al subunit of intestinal smooth muscle and other tissues. Eur J Biochem 222: 195–202
Feron O, Salomone S, Godfraind T (1996) Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Br J Pharmacol 118 (3) 659–664
Finet M, Godfraind T, Khoury G (1985) The positive inotropic action of a nifedipine analogue, Bay K 8644, in guinea-pig and rat isolated cardiac preparations. Br J Pharmacol 86: 27–32
Godfraind T, Kaba A (1969) Blockade or reversal of contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br J Pharmacol 36: 549–560
Godfraind T, Polster P (1968) Etude comparative de médicaments inhibant la réponse contractile de vaisseaux isolés d’origine humaine ou animale. Thérapie 23: 1209–1220
Godfraind T, Salomone S (1996) Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc Drugs Ther 10 (4): 439–446
Godfraind T, Salomone S (1997) New advances in hypertensive treatment with calcium antagonists. J Cardiovasc Pharmacol 30 (Suppl 2): S1 - S5
Godfraind T (1994) Calcium antagonists and vasodilatation. Pharmacol Ther 64 (1): 3775
Godfraind T, Kaba A, Polster P (1966) Specific antagonism to the direct and indirect action of angiotensin on the isolated guinea-pig ileum. Br J Pharmacol Chemother 28: 93–104
Godfraind T, Miller RC, Wibo M (1986a) Calcium antagonism and calcium entry blockade. Pharmacol Rev 38: 321–416
Godfraind T, Morel N, Wibo M (1986b) The heterogeneity of calcium movements in cardiac and vascular smooth muscle cells. Scand J Clin Lab Invest 46 (Suppl 180): 29–40
Godfraind T, Eglème C, Finet M, Jaumin P (1987) The actions of nifedipine and nisoldipine on the contractile activity of human coronary arteries and human cardiac tissue in vitro. Pharmacol Toxic 61: 79–84
Godfraind T, Morel N, Wibo M (1988) Tissue specificity of dihydropyridine-type calcium antagonists in human isolated tissues. Trends Pharmacol Sci 9: 37–39
Godfraind T, Kazda S, Wibo M (1991) Effects of a chronic treatment by nisoldipine, a calcium antagonistic dihydropyridine, on arteries of spontaneously hypertensive rats. Circ Res 68: 674–682
Godfraind T, Dessy C, Salomone S (1992a) A comparison of the potency of selective L-calcium channel inhibitors in human coronary and internal mammary arteries exposed to serotonin. J Pharmacol Exp Ther 263: 112–122
Godfraind T, Morel N, Salomone S (1992b) Characterization in human coronary arteries of the binding sites responsible for the pharmacologic action of amlodipine: a comparison with animal vascular tissues. J Cardiovasc Pharmacol 20 (Suppl A): S33 - S39
Godfraind T, Salomone S, Dessy C, Verhelst B, Dion R, Schoevaerts JC (1992c) Selectivity scale of calcium antagonists in the human cardiovascular system (based on in vitro studies). J Cardiovasc Pharmacol 20 (Suppl 5): S34 - S41
Hansen JF (1998) Is the safety and efficacy of calcium antagonists now established? Cardiovasc Drugs Ther 12: 145–147
Kaplan NM (1998a) Commentary on the sixth report of the Joint National Committee (JNC-6). Am J Hypertens 11 (1 Pt 1): 134–136
Kaplan NM (1998b) The 6th joint national committee report (JNC-6): new guidelines for hypertension therapy from the USA. Keio J Med 47 (2): 99–105
Kazda S, Garthoff B, Meyer H, Schloßmann K, Stoepel K, Towart R, Vater W, Wehinger E (1980) Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4 dihydro-2,6-demethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylate (nisoldipine, Bay k 5552). Arzneim Forsch 30: 2144–2162
Kyselovic J, Morel N, Wibo M, Godfraind T (1998a) Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. J Hypertens 16 (10): 1515–1522
Kyselovic J, Salomone S, Wibo M, Godfraind T (1998b) Effect of nifedipine on salt-dependent cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Br J Pharmacol 123: 320 P
Leonetti G, Cuspidi C, Sampieri L, Terzoli L, Zanchetti A (1982) Comparison of cardiovascular, renal and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 4: S319 - S324
Mancia G, Grassi G (1997) Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial. J Cardiovasc Pharmacol 30 (5): 548–553
Mancia G, Grassi G (1998) Antihypertensive treatment: past, present and future. J Hypertens 16 (1): S1 - S7
Mancia G, Omboni S, Grassi G (1997a) Combination treatment in hypertension: the Vera Tran Study. Am J Hypertens 7 (Pt 2): 153S - 158S
Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A (1997b) Blood-pressure control in the hypertensive population Lancet 349 (9050): 454–457
Mathew V, Hasdai D, Lerman A (1996) The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 71: 769–777
Messerli FH (1996) What, if anything, is controversial about calcium antagonists? Am J Hypertens l2 (Pt 2): 177S - 181S
Messerli FH, Schmieder RE, Weir MR (1997) Salt. A perpetrator of hypertensive target organ disease? Arch Intern Med 157: 2449–2452
Morel N, Godfraind T (1987) Prolonged depolarization increases the pharmacological effect of dihydropyridines and their binding affinity for calcium channel of vascular smooth muscle. J Pharmacol Exp Ther 243: 711–715
Morel N, Godfraind T (1994) Selective interaction of the calcium antagonist amlodipine with calcium channels in arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 24: 524–533
Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T (1998) The action of calcium channel blockers on recombinant L-type calcium channel al subunit. Br J Pharmacol 125: 1005–1012
Opie LH (1990) Clinical use of calcium channel antagonist drugs. 2nd edn. Kluwer, Boston
Rossi GP et al (1999) Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation 99: 1147–1155
Schwartzkopff B, Strauer BE (1999) Squeezing tubes: a case of remodeling and regulation: coronary reserve in hypertensive heart disease. Cardiovasc Res 40: 4–8
Spedding M, Fraser S, Clarke B, Patmore L (1990) Factors modifying the tissue selectivity of calcium antagonists. J Neural Transm 1. 5–16
Wibo M, De Roth L, Godfraind T (1988) Pharmacologic relevance of dihydropyridine binding sites in membrane from rat aorta: kinetic and equilibrium studies. Circ Res 62: 91–96
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Godfraind, T. (1999). The Coronary Selectivity of Calcium Antagonists — Focus on CHD. In: Rousseau, M.F. (eds) Nisoldipine Coat-Core. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60220-7_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-60220-7_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-66049-1
Online ISBN: 978-3-642-60220-7
eBook Packages: Springer Book Archive